Status:

UNKNOWN

Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Conditions:

Brain and Central Nervous System Tumors

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II t...

Detailed Description

OBJECTIVES: Primary * To assess the impact of high-dose radiotherapy (RT) on progression-free survival (PFS), treatment tolerance, and post-treatment global cognitive functioning in patients with at...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed newly diagnosed meningioma, including the following subtypes:
  • Atypical WHO grade II meningioma greater than or equal to 4 mitosis per high-power field \[HPF\] or the presence of at least 3 of the following variables:
  • Cellularity
  • Architectural sheeting (i.e., patternless pattern)
  • Macronuclei cell formation
  • Small cell formation
  • Malignant WHO grade III meningioma
  • All locations allowed except for optic nerve sheets tumors
  • Complete or subtotal resection as assessed by the surgeon after verification with a postoperative MRI and according to Simpson guidelines
  • No neurofibromatosis type 2 (NF-2)
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-2
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during study therapy
  • May be registered on this trial only once
  • No clinical evidence of second malignancies except carcinoma in situ of the cervix or basocellular carcinoma
  • No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • PRIOR CONCURRENT THERAPY:
  • No prior radiotherapy to the brain or meninges interfering with the protocol treatment plan

Exclusion

    Key Trial Info

    Start Date :

    December 1 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    78 Patients enrolled

    Trial Details

    Trial ID

    NCT00626730

    Start Date

    December 1 2007

    Last Update

    February 3 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Hopital Cantonal Universitaire de Geneve

    Geneva, Switzerland, CH-1211